RNAZ
Transcode Therapeutics Inc
NASDAQ: RNAZ · HEALTHCARE · BIOTECHNOLOGY
$1.74
+4.19% today
Updated 2026-10-28
Market cap
$28.88M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-52.06
Dividend yield
—
52W range
$2 – $13
Volume
0.1M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.5
Quality
C+3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-1.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$10.00
+474.71%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -1.37 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-5.40M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-17.56M | $-18.55M | $-16.75M | $-34.66M | $-6.70M |
| EPS | — | — | — | — | $-52.06 |
| Free cash flow | $-15.86M | $-18.11M | $-13.36M | $-19.52M | $-5.40M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Transcode Therapeutics Inc trades at $1.74. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -1.37, it sits in the distress.
Frequently asked questions
What is Transcode Therapeutics Inc's stock price?
Transcode Therapeutics Inc (RNAZ) trades at $1.74.
Is Transcode Therapeutics Inc overvalued?
Transcode Therapeutics Inc carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Transcode Therapeutics Inc (RNAZ)?
The 12-month analyst consensus target is $10.00, about 474.7% above the current $1.74. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Transcode Therapeutics Inc's Altman Z-Score is -1.37, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-27.93%
Beta1.26
50D MA$1.95
200D MA$6.28
Shares out0.02B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—